We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$7.33M
Cap. Flow
+$5.92K
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
2
Reduced
–
Closed
–
Avg Time Held Equity + Options
10 quarters
Top 10 Avg Time Held Equity + Options
10 quarters
Top 20 Avg Time Held Equity + Options
10 quarters
Avg Time Held Equity only
10 quarters
Top 10 Avg Time Held Equity only
10 quarters
Top 20 Avg Time Held Equity only
10 quarters

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$5.92K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.5%
2 Miscellaneous 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BHVN icon
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$162M 63.94%
1,111,111
– –
2018 Q4
14 quarters
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$46.8M 18.49%
31,841,394
+8,060
+0% +$5.92K
2019 Q4
10 quarters
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.14B
$40.7M 16.07%
3,846,154
– –
2021 Q4
2 quarters
EPZM
4
CALL
DELISTED
Epizyme, Inc
EPZM
$3.79M 1.5%
2,575,450
+27,166
+1% +$20K
2019 Q4
10 quarters
VIRX icon
5
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$18K 0.01%
3,700
– –
2018 Q4
14 quarters

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q2 2022 Portfolio in Review

As of Q2 2022, RP Management held 5 positions worth $253M, up 3% from $246M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 0%. RP Management opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

  • RP Management added most to Epizyme, Inc in Q2 2022, an estimated $5.92K increase.
  • RP Management's ten largest holdings make up 100% of its $253M portfolio in Q2 2022.
  • RP Management opened 0 new positions and closed 0 in Q2 2022.
  • RP Management's portfolio value rose 3% quarter-over-quarter to $253M.

Based on RP Management's 13F filing for Q2 2022, filed 10 Aug 2022.